Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
About this item
Full title
Author / Creator
COSMIC-313 Investigators , Choueiri, Toni K. , Powles, Thomas , Albiges, Laurence , Burotto, Mauricio , Szczylik, Cezary , Zurawski, Bogdan , Yanez Ruiz, Eduardo , Maruzzo, Marco , Suarez Zaizar, Alberto , Fein, Luis E. , Schutz, Fabio A. , Heng, Daniel Y.C. , Wang, Fong , Mataveli, Fabio , Chang, Yu-Lin , van Kooten Losio, Maximiliano , Suarez, Cristina and Motzer, Robert J.
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In patients with advanced renal-cell carcinoma, treatment with cabozantinib plus nivolumab and ipilimumab resulted in longer progression-free survival than treatment with nivolumab and ipilimumab alone.
Alternative Titles
Full title
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
Authors, Artists and Contributors
Author / Creator
Choueiri, Toni K.
Powles, Thomas
Albiges, Laurence
Burotto, Mauricio
Szczylik, Cezary
Zurawski, Bogdan
Yanez Ruiz, Eduardo
Maruzzo, Marco
Suarez Zaizar, Alberto
Fein, Luis E.
Schutz, Fabio A.
Heng, Daniel Y.C.
Wang, Fong
Mataveli, Fabio
Chang, Yu-Lin
van Kooten Losio, Maximiliano
Suarez, Cristina
Motzer, Robert J.
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10257898
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10257898
Other Identifiers
ISSN
0028-4793,1533-4406
E-ISSN
1533-4406
DOI
10.1056/NEJMoa2212851
